RHO5.DU : Summary for ROCHE HLDG AG GEN. - Yahoo Finance

U.S. Markets close in 5 hrs 42 mins

ROCHE HLDG AG GEN. (RHO5.DU)


Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
Add to watchlist
228.20+0.30 (+0.13%)
As of 8:27AM CET. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close227.90
Open228.20
Bid230.51 x
Ask230.55 x
Day's Range228.20 - 228.20
52 Week Range224.80 - 231.60
Volume91
Avg. Volume78
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals
    Investor's Business Daily18 hours ago

    Merck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals

    Merck and Roche are swiping share from Bristol-Myers Squibb's I-O drugs after their FDA approvals in advanced lung cancer.

  • Reuters6 days ago

    Roche says Phase II trial supports twin treatment for kidney cancer

    Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The tests showed promising effectiveness compared with the standard treatment for mRCC, sunitinib, which is sold by Pfizer under the brand name Sutent.

  • These Are The First Immune-System Cancer Drugs OK'd By FDA
    Investor's Business Daily7 days ago

    These Are The First Immune-System Cancer Drugs OK'd By FDA

    A handful of products define the new market for drugs that harness the immune system to fight cancer. Here's a list of the drugs and their FDA-approved uses.